Quantification of acetaminophen and its metabolites in plasma using UPLC-MS by Flint, R.B. (Robert) et al.
Therapeutic Drug Monitoring Publish Ahead of Print
DOI: 10.1097/FTD.0000000000000379
1 
 
 1 
 2 
Full title:  3 
Quantification of acetaminophen and its metabolites in plasma using 4 
UPLC-MS: doors open to therapeutic drug monitoring in special patient 5 
populations 6 
 7 
Short title:  8 
Quantification of acetaminophen and its metabolites 9 
 10 
Robert B. Flint, PharmD
1,2, 3
, Paola Mian, PharmD
4
, Bart van der Nagel, BSc
1
, 11 
Nuria Slijkhuis, BSc
1
, Birgit C.P. Koch, PharmD, PhD
1*
 12 
1. Department of Pharmacy, Erasmus University Medical Center, 13 
Rotterdam, the Netherlands
 
14 
2. Department of Pediatrics, Division of Neonatology, Erasmus University 15 
Medical Center—Sophia, Rotterdam, the Netherlands
 
16 
3. Department of Pharmacy, Radboudumc, Nijmegen, the Netherlands
 
17 
4. Intensive Care and Department of Pediatric Surgery, Erasmus 18 
University Medical Center—Sophia, Rotterdam, the Netherlands
 
19 
 20 
Corresponding author 21 
R.B. Flint 22 
Erasmus University Medical Center 23 
A
CE
TE
D
Copyright  2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
2 
 
Department of Pharmacy 24 
Postal Box 2040 25 
3000 CA Rotterdam 26 
The Netherlands 27 
Email:  r.flint@erasmusmc.nl 28 
Phone:  +31 107033202 29 
Fax:   +31 107032400 30 
 31 
Conflicts of Interest and Source of Funding 32 
The authors declare that they have no conflict of interest nor have they 33 
received funding. 34 
 35 
ABSTRACT 36 
Background: Acetaminophen (APAP, paracetamol) is the most commonly 37 
used drug for pain and fever in both the United States and Europe and 38 
considered safe when used at registered dosages. Nevertheless, differences 39 
between specific populations lead to remarkable changes in exposure to 40 
potentially toxic metabolites. Furthermore, extended knowledge is required 41 
on metabolite formation following intoxication, to optimize antidote 42 
treatment. Therefore, the authors aimed to develop and validate a quick 43 
and easy analytical method for simultaneous quantification of APAP, APAP-44 
glucuronide, APAP-sulfate, APAP-cysteine, APAP-glutathione, APAP-45 
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mercapturate, and protein-derived APAP-cysteine in human plasma by ultra-46 
performance liquid chromatography-electrospray ionization-tandem mass 47 
spectrometry (UPLC-MS/MS). 48 
Methods: The internal standard was APAP-D4 for all analytes. 49 
Chromatographic separation was achieved with a reversed-phase Acquity 50 
UPLC HSS T3 column with a runtime of only 4.5 minutes per injected sample. 51 
Gradient elution was performed with a mobile phase consisting of 52 
ammonium acetate, formic acid in Milli-Q ultrapure water or in methanol at 53 
flow rate of 0.4 mL/min. 54 
Results: A plasma volume of only 10 µL was required to achieve both 55 
adequate accuracy and precision. Calibration curves of all six analytes were 56 
linear. All analytes were stable for at least 48 hours in the autosampler; the 57 
high quality control of APAP-glutathione was stable for 24 hours. The 58 
method was validated according to the US Food and Drug Administration 59 
guidelines. 60 
Conclusions: This method allows quantification of acetaminophen and six 61 
metabolites, which serves purposes for research, as well as therapeutic drug 62 
monitoring (TDM). The advantage of this method is the combination of 63 
minimal injection volume, a short runtime, an easy sample preparation 64 
method, and the ability to quantify acetaminophen and all six metabolites. 65 
 66 
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Acetaminophen, metabolites, UPLC-MS/MS, therapeutic drug monitoring, 68 
pharmacokinetics 69 
 70 
INTRODUCTION 71 
Acetaminophen (APAP, N-Acetyl-p-Aminophenol, or paracetamol) is 72 
the most commonly used drug for pain and fever in both the United States 73 
and Europe [1]. Acetaminophen is generally safe when used at registered 74 
dosages, thereby titrated upon effect, with a maximum of 4 g/day in four 75 
doses for adults. In children, dosage depends on age and weight as follows: 76 
with <1 month—30-60 mg/kg/day in three doses; with age >1 month—up 77 
to 90 mg/kg/day in four doses [2]. On the other hand, administration of 78 
supratherapeutic doses of acetaminophen is the leading cause for liver 79 
failure in the United States [3], mainly influenced by its drug metabolism. 80 
This metabolism has been reported to deviate in (premature) neonates [4], 81 
obese patients [5], and following supratherapeutic doses [6]. Such variability 82 
in exposure to potentially toxic metabolites can be expected in other 83 
specific populations as well, e.g., anorexic patients, patients from different 84 
ethnical backgrounds, extreme elderly, pregnant women and their fetuses 85 
[7], and in patients with drug- or genetically driven changes in CYP1A2 86 
activity, e.g., omeprazole induction. 87 
Acetaminophen is largely metabolized in the liver, predominantly by 88 
sulfation and glucuronidation (Figure 1). In adults, sulfation encompasses 89 
about 30% and glucuronidation about 55% [8-10]; only 2%-5% is excreted 90 
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unchanged in the urine [9, 10]. Approximately 5%-10% of acetaminophen is 91 
metabolized by cytochrome P450 (CYP), primarily by CYP2E1 [11-13], to the 92 
toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) [9, 14-16]. At 93 
therapeutic doses, NAPQI is immediately inactivated by conjugation with 94 
glutathione. However, without this detoxification route, NAPQI binds 95 
covalently to cellular proteins and forms toxic protein adducts, such as 96 
protein-derived acetaminophen-cysteine (APAP-cysteine). These protein 97 
adducts may cause mitochondrial dysfunction and early oxidant stress [17-98 
19]. Consequently, hepatotoxicity can be caused by liver cell necrosis [3]. 99 
Although it was thought that depletion of 70% of total liver glutathione 100 
would be necessary for NAPQI to begin with protein binding [20], protein-101 
derived APAP-cysteine was detected in serum from human after therapeutic 102 
doses [21]. It is likely that either a threshold of protein-derived APAP-103 
cysteine needs to be exceeded for the development of toxicity or that 104 
specific binding targets are spared at therapeutic doses [6]. 105 
Currently, acetaminophen concentrations have only been considered 106 
important to measure for patients who are suspected of intake of a toxic 107 
amount and for patients who show a decreased hepatic function. In that 108 
case, acetaminophen is mostly analyzed with an immunoassay, not 109 
measuring metabolites, despite their key role in acetaminophen 110 
hepatotoxicity. Considering acetaminophen-metabolic routes, further 111 
investigation for associations between exposure to acetaminophen 112 
metabolites and toxicity is warranted, as well as exposure in specific 113 
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populations. In the case of acetaminophen intoxication, extended 114 
knowledge of metabolite formation will assist in optimizing (antidote) 115 
treatment. This also applies to intoxication upon chronic use of high 116 
acetaminophen dosages. Currently, there remains a knowledge gap 117 
regarding the optimal treatment with N-acetylcysteine infusion to prevent 118 
or treat hepatotoxicity. These new insights suggest Therapeutic Drug 119 
Monitoring (TDM) of metabolites in case of toxicity, or as part of standard 120 
clinical care in certain populations. Ultimately, monitoring of APAP-121 
metabolite concentrations may prevent or reduce toxicity and optimize 122 
therapy. 123 
We developed and validated an analytical method for simultaneous 124 
quantification of APAP, APAP-glucuronide, APAP-sulfate, APAP-cysteine, 125 
APAP-glutathione, APAP-mercapturate, and protein-derived APAP-cysteine 126 
in a minimal volume of human plasma by ultra-performance liquid 127 
chromatography-electrospray ionization-tandem mass spectrometry (UPLC-128 
MS/MS), preceded by an easy sample preparation. We aimed to optimize 129 
the sensitivity of the assay to minimize the required sample volume, which 130 
allows measurement of the smallest volume samples from preterm infants. 131 
 132 
MATERIALS AND METHODS 133 
Chemicals and reagents 134 
APAP, APAP-sulfate, APAP-mercapturate, APAP-glucuronide, and 135 
APAP-cysteine solution were purchased from Santa Cruz Biotechnology 136 
CC
EP
TE
D
Copyright  2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
7 
 
(Heidelberg, Germany). APAP-glutathione was obtained from Toronto 137 
Research Chemicals (Eching, Germany) and APAP-D4 solution from Sigma 138 
Aldrich Cerilliant (Zwijndrecht, The Netherlands). Methanol absolute LC-MS 139 
grade and formic acid 99% ULC/MS grade were purchased from Biosolve BV 140 
(Valkenswaard, The Netherlands). Water was purified by using a MilliPore 141 
Advantage A10 system. External quality control samples for acetaminophen 142 
were purchased from Stitching Kwaliteitsbewaking Klinische 143 
Geneesmiddelanalyse en Toxicologie (KKGT, The Hague, The Netherlands) 144 
and Santa Cruz Biotechnology (Heidelberg, Germany). 145 
 146 
Stock solutions, calibrators, quality control samples, and internal standard 147 
Stock solutions of APAP, APAP-sulfate, APAP-glucuronide, and APAP-148 
cysteine were prepared at a concentration of 500 mg/L using methanol, 149 
while stock solutions of APAP-mercapturate and APAP-glutathione were 150 
prepared at a concentration of 100 mg/L using methanol. For each analyte, 151 
two separate stock solutions were prepared with the same concentration, 152 
for both calibration of standard samples and for QC samples. Stock solutions 153 
were stored at −20 °C. 154 
The working solution, calibrator 8 (50 mg/L), was prepared by drying 155 
500 µL of APAP, APAP-sulfate, APAP-glucuronide, and APAP-cysteine, and 156 
2500 µL of APAP-mercapturate and APAP-glutathione in one glass tube at 40 157 
°C under nitrogen flow until all methanol was evaporated. Subsequently, all 158 
analytes were reconstituted in 5-mL human plasma and mixed for 30 159 
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seconds. Calibrators 1 through 7 (0.05–25 mg/L) and the lower limit of 160 
quantification (LLOQ) standard (0.01 mg/L) were prepared by diluting 161 
calibrator 8 with human plasma. Quality control (QC) samples were 162 
prepared the same way, using the other stock solution. The working solution 163 
was diluted with human plasma to get three concentrations: QC Low (0.20 164 
mg/L), QC Medium (1.5 mg/L), and QC High (15 mg/L). Then, calibrators and 165 
QC samples were transferred in 10-µL portions to 1.5-mL tubes (Eppendorf) 166 
and stored at −80 °C awaiting analysis. 167 
The internal standard (IS) was APAP-D4. A working solution of the 168 
internal standard was prepared in methanol at a concentration of 100 µg/L 169 
APAP-D4. 170 
 171 
Specimens 172 
Human blank plasma was obtained from the blood transfusion 173 
laboratory of the Erasmus Medical Center Rotterdam. Because 174 
acetaminophen is a regularly used drug, acetaminophen-free blood was 175 
collected from volunteers. Blood was centrifuged to separate plasma from 176 
the red blood cells. Plasma was pooled and collected in smaller tubes. These 177 
tubes were stored at −20 °C awaiting analysis. 178 
 179 
Sample preparation 180 
All calibrators, QC samples, blank and patient samples were thawed at 181 
least half an hour prior to preparation. Then, to 10 µL of each standard and 182 
AC
CE
PT
ED
Copyright  2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
9 
 
sample, 40 µL of internal standard solution was added for protein 183 
precipitation. The samples were mixed for 15 seconds and then centrifuged 184 
for 5 minutes at 16000 x g. Of about 30 µL of supernatant was taken from 185 
each sample and transferred to amber auto sampler insert vials (VWR). 186 
Next, 140 µL of 0.1% aqueous formic acid was added and the samples were 187 
mixed for 15 seconds. The ratio of the aqueous and organic solvent in the 188 
sample matched the ratio in the mobile phase at start of the gradient. The 189 
blank sample, without internal standard, was prepared by adding 40 µL of 190 
methanol instead of internal standard solution. For acetaminophen, 191 
acetaminophen-D4, and APAP-cysteine, 4 µL of sample was injected into the 192 
UPLC-MS/MS apparatus. For all the other analytes, 10 µL was injected 193 
because of the lower sensitivity for these analytes. 194 
 195 
Protein-derived APAP-cysteine 196 
For quantification of protein-derived APAP-cysteine in patient 197 
samples, the sample preparation was preceded with one extra step after 198 
thawing the sample: The protein-bound fraction was removed by filtration 199 
of an extra 130-µL plasma through an Amicon Ultra-0.5 Centrifugal Filter 200 
Unit with Ultracel-10 membrane (Merck Chemicals, Amsterdam, The 201 
Netherlands) and discarded afterward, in order to collect 10-µL plasma with 202 
unbound APAP-cysteine. The concentration of protein-derived APAP-203 
cysteine is determined by calculating the difference in APAP-cysteine 204 
concentrations before and after filtration. The sample was further prepared 205 
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as described for all other analytes, continuing with the addition of 40 µL of 206 
internal standard. 207 
 208 
Instrumentation 209 
The equipment used was a Dionex Ultimate UPLC system consisting of 210 
an Ultimate 3000 RS UPLC pump, an Ultimate 3000 RS autosampler and an 211 
Ultimate 3000 RS Column Compartment. The UPLC was connected to a triple 212 
quadrupole Thermo TSQ Vantage MS with HESI probe (Thermo Scientific). 213 
The software programs Chromeleon (version 6.8, Dionex, Thermo Scientific), 214 
Xcalibur (version 2.1, Thermo Scientific), and LCquan (version 2.6, Thermo 215 
Scientific) were used to control the system and analyze the data. 216 
 217 
UPLC conditions 218 
Chromatographic separation, based on affinity of the analytes with the 219 
nonpolar stationary phase, was achieved with a reversed-phase Acquity 220 
UPLC HSS T3 column (1.8 µm, 2.1 × 100 mm; High Strength Silica with a 221 
bound trifunctional C18 alkyl phase). Gradient elution was performed with a 222 
mobile phase consisting of 1 mL of a 154 mg/L solution of ammonium 223 
acetate in formic acid (99%) in 1 L of Milli-Q ultrapure water (eluent A) and 1 224 
mL of the same solution in 1 L of methanol (eluent B). Prior to the analysis, 225 
the system was equilibrated at the starting conditions of 86% eluent A and 226 
14% eluent B until pressure was stable. The multistep gradient was as 227 
follows: from 0 to 0.8 minutes, eluent B was increased from 14% to 28%; 228 
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from 0.8 to 1.0 minute, eluent B was increased to 95%; from 1.0 to 2.0 229 
minutes, eluent B was kept stable at 95%; from 2.0 to 2.2 minutes, eluent B 230 
was decreased to 14%; from 2.2 to 5.3 minutes, eluent B was kept stable at 231 
14%. The run ended at 5.3 minutes at starting conditions. The flow was kept 232 
at 0.400 mL/minute during the entire runtime. The temperature for the 233 
column oven was set at 40 °C and for the autosampler at 15 °C. In order to 234 
quantify all analytes, a volume of 4 µL as well as 10 µL is injected, which 235 
requires two runs per sample and therefore doubles the runtime to 10.6 236 
minutes. For the quantification of protein-derived APAP-cysteine, a third run 237 
is required. 238 
 239 
MS/MS conditions 240 
For the detection and quantification of acetaminophen and 241 
metabolites, settings of the MS/MS were as follows: MS runtime of 4.5 242 
minutes, experiment type was Selected Reaction Monitoring (SRM), 243 
ionization at ESI+, spray voltage of 4000 V, vaporizer temperature at 375 °C, 244 
sheath gas pressure with nitrogen at 50 psi, auxiliary gas pressure with 245 
nitrogen at 20 psi, capillary temperature at 250 °C, and collision pressure at 246 
1.5 mTorr. All other settings were specific for each analyte and were 247 
determined by infusion experiments with academic solutions of each 248 
analyte of 1 mg/L. The chosen transitions and settings are shown in Table 1. 249 
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 250 
Assay validation 251 
Validation of the method was performed according to the US Food 252 
and Drug Administration (2001) guidelines for bioanalytical methods [22]. 253 
The following validation parameters were investigated. 254 
 255 
Linearity 256 
The relation between the concentration of the calibrators and 257 
response (ratio of peak areas of the analytes and the internal standard) was 258 
tested with a calibration curve. This curve should be linear across the range 259 
from 0.05 up to 50 mg/L. To make the calibration curve, eight calibrators 260 
were prepared and analyzed. Linear least square regression was used to 261 
analyze the data. It was decided to apply weighting 1/x, which means that 262 
calibrators with the lowest concentrations are more important for the 263 
calibration line than calibrators with highest concentrations [23]. The 264 
relative standard deviation (RSD) was required to be lower than 15%, and 265 
the correlation coefficient (r) together with the determination coefficient 266 
(r
2
) were required to be at least 0.9950 and 0.9900, respectively. 267 
 268 
LLOQ and ULOQ 269 
The LLOQ was measured by analyzing the LLOQ calibrator (0.01 or 0.05 270 
mg/L) six times in a row. Mean and standard deviation of the response 271 
ratios of the six samples were measured. Imprecision and accuracy were 272 
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calculated and should be ≤20% and between 80% and 120%, respectively. 273 
The highest calibrator of the calibration curve was used as upper limit of 274 
quantification (ULOQ). 275 
 276 
Accuracy 277 
Accuracy was measured by analyzing three QC concentrations (n = 6 278 
for each concentration). The percentage deviation between measured 279 
concentration and theoretical concentration was calculated, and should be 280 
lower than 15%. 281 
 282 
Repeatability and reproducibility 283 
Repeatability was tested by analyzing three QC concentrations in six-284 
fold on the same day. For each concentration, mean and RSD were 285 
calculated. Reproducibility was tested by analyzing each QC concentration in 286 
duplicate on six different days. The mean response of the 12 concentrations 287 
for each sample with their RSD was calculated. For both tests, RSD was 288 
required to be lower than 15%. 289 
 290 
Stability 291 
In-process stability was determined by storing QC samples of three 292 
concentrations (n = 2 per concentration) at 6 °C prior to preparation for 24 293 
and 48 hours. Autosampler stability was determined by storing QC samples 294 
(n = 2 per concentration) after sample preparation in the autosampler for 295 
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24, 48, and 72 hours. Response ratios were measured and compared with 296 
response ratios of samples kept at −80 °C prior to preparation. After sample 297 
preparation, samples were directly analyzed. Recovery was required to be 298 
between 90% and 110%. 299 
 300 
Matrix effect and recovery 301 
It is important to measure matrix effects and absolute recoveries in 302 
the development of an LC-MS/MS method since ion suppression and ion 303 
enhancement effects can be expected owing to interferences by matrix 304 
compounds, stable-isotope-labeled internal standards and co-eluting 305 
compounds [24]. In order to check whether the precision, the 306 
reproducibility, and the stability of the concentration-signal ratio are 307 
affected by interference of the matrix analytes, the method described by 308 
Matuszewski et al. (2003) was used [25]. Five different lots of human plasma 309 
were used. To two QC concentration levels (QC low and QC high) and a 310 
blank sample (all three in duplicate), analytes were added before extraction. 311 
The same set of QCs and blanks was prepared with the analytes added after 312 
extraction. Also, a set of six samples was evaluated with only Milli-Q 313 
ultrapure water instead of plasma. Matrix effects were calculated as follows: 314 
(peak area of analyte spiked after extraction) / (peak area of analyte 315 
prepared in Milli-Q ultrapure water) × 100%. 316 
The recovery was calculated as the percentage ratio of the area of the 317 
analytes spiked before extraction and the ones prepared in Milli-Q ultrapure 318 
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water. The mean and RSD were calculated of both matrix effects and 319 
recovery. In the ideal situation, the mean matrix effects and recovery are 320 
between 80% and 120% and the RSD of both parameters is ≤15%. 321 
Furthermore, for each analyte, the IS-normalized matrix effect should also 322 
be calculated by dividing the matrix effect of the analyte by the matrix effect 323 
of the IS. The RSD of the IS-normalized matrix effect calculated from the 324 
different lots of matrix should not be greater than 15%. 325 
 326 
Application to pediatric pharmacokinetic samples 327 
For the validation of the assay for clinical practice and research 328 
purposes, the method has been applied to quantify acetaminophen and its 329 
metabolites in plasma of children participating in a pediatric clinical study. 330 
This observational prospective study was performed at the Department of 331 
Anaesthesia and Intensive Care Medicine of Our Lady’s Children’s Hospital, 332 
Dublin, Ireland, between January and November 2012. Children (with and 333 
without Down’s Syndrome) routinely received acetaminophen post-cardiac 334 
surgery in a dose of 7.7 mg/kg for children below 10 kg bodyweight, and 15 335 
mg/kg for children above 10 kg bodyweight. The study protocol was 336 
approved by the local ethics committee. 337 
 338 
 339 
 340 
 341 
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RESULTS 342 
Linearity 343 
Linearity was achieved for each analyte in the range between the 344 
LLOQ and the ULOQ (Table 2), with all RSDs to be lower than 15% and the 345 
determination coefficient (r
2
) to be 0.998 at the lowest. APAP was linear 346 
from calibrator 1 up to and including 7; APAP-mercapturate and APAP-347 
cysteine from calibrator 1 up to and including 6; APAP-sulfate from 348 
calibrator 2 up to and including 8; APAP-glucuronide, APAP-glutathione from 349 
calibrator 1 up to and including 8. Quantification performance of protein-350 
derived APAP-cysteine is subject to those of APAP-cysteine, with the step of 351 
filtration being the single difference. 352 
 353 
LLOQ and ULOQ 354 
The results of determination of LLOQ and ULOQ are shown in Table 2. 355 
 356 
Accuracy, repeatability, and reproducibility 357 
The accuracy, repeatability, and reproducibility data all met the 358 
requirement of being less than 15%, except for the APAP-cysteine accuracy 359 
of 30.9% (error of measurement) for QC high. The results are shown in Table 360 
2. 361 
 362 
 363 
 364 
AC
CE
PT
ED
Copyright  2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
17 
 
Stability 365 
Except for APAP-glutathione, the recovery of all QCs was between 90% 366 
and 110%, indicating that they were stable for at least 48 hours when stored 367 
at 6 °C. APAP-glutathione was only stable for 24 hours. All prepared QCs 368 
were stable for at least 48 hours when kept in the autosampler. The effect 369 
of drying showed no significant difference between the dried and non-dried 370 
standard (Mann Whitney test; p < 0.05). 371 
 372 
Matrix effect and recovery 373 
Matrix effects and absolute recoveries in the development of the LC-374 
MS/MS method are shown in Table 3. The test of Matuszwewski showed 375 
that APAP, APAP-cysteine, and APAP-sulfate experienced neither matrix 376 
effect nor an effect from the sample preparation. Concerning APAP-377 
glucuronide though, 191.2% matrix effect indicates ion enhancement. On 378 
the other hand, for APAP-mercapturate, ion suppression was observed; 379 
matrix effect was 72.0%. A good recovery was achieved for all analytes, 380 
except for APAP-glutathione with mean 18.6%. 381 
 382 
Application to pediatric pharmacokinetic samples 383 
A total of 162 post-dose samples were collected from a pediatric 384 
cohort (n = 30), consisting of children with Down’s Syndrome (n = 17) and 385 
without Down’s Syndrome (n = 13) (data unpublished); median age at 386 
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surgery was 176 days (range 92-944), median weight at cardiac surgery 6.1 387 
kg (4-12.9).  388 
For APAP, APAP-cysteine, APAP-glucuronide, and APAP-sulfate, only 1 389 
of the 162 (0.6%) samples was measured below LLOQ. For APAP-390 
mercapturate and APAP-glutathione, this was the case in 5 (3.1%) and 161 391 
(99.4%) samples, respectively. None of the analytes was measured above 392 
the ULOQ in these samples. Due to the small sample volume, it was not 393 
possible to differentiate between protein bound and unbound APAP-394 
cysteine. 395 
 396 
DISCUSSION 397 
We have validated an UPLC-MS method for the quantification of 398 
acetaminophen and its metabolites according to US Food and Drug 399 
Administration guidelines, with an easy sample preparation, short runtime, 400 
and minimal injection volume. Therefore, the assay is very suitable for TDM. 401 
The metabolites incorporated in this method are APAP-glucuronide, APAP-402 
sulfate, APAP-glutathione, APAP-cysteine, APAP-mercapturate, and protein-403 
derived APAP-cysteine. Prior reported methods for the quantification of 404 
acetaminophen and metabolites in human plasma contained few 405 
metabolites, mostly acetaminophen sulfate and/or glucuronide [26-28]. 406 
Assays with more metabolites were prior validated in animal matrices [29], 407 
although Cook et al. recently published a method in human plasma and 408 
urine that comes close to the performance of our assay [30]. Our assay is 409 
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distinguished by a shorter total runtime per injection of 5.3 minutes versus 410 
20 minutes, easier sample preparation, and the ability to quantify the toxic 411 
metabolite protein-derived APAP-cysteine. 412 
Our assay fulfilled the desired criteria for accuracy, repeatability, and 413 
reproducibility, except for the 30.9% accuracy of QC high of APAP-cysteine. 414 
This QC high concentration of APAP-cysteine was outside the linear range. 415 
The overestimation of APAP-cysteine could be caused by transformation 416 
from the instable APAP-glutathione. At therapeutic doses, the 417 
acetaminophen ULOQ is generally not exceeded, although it may be for 418 
toxicology purposes. The ranges for linearity for all other analytes were 419 
perfectly suitable for clinical pharmacology and toxicology. 420 
Relevant matrix effects were measured for APAP-glucuronide during 421 
the experiment, resulting in an increased process efficiency. This is in line 422 
with the general problematic behavior of glucuronide-metabolites in LC-423 
MS/MS analyses, due to their susceptibility to interferences from the co-424 
eluting matrix analytes [31]. On the other hand, for APAP-mercapturate, 425 
matrix effects lead to observed ion suppression. The coefficients of variation 426 
of APAP-mercapturate in the samples spiked before extraction are 5.8% and 427 
4.7% for QC-L and QC-H, respectively. Therefore, the effect of the matrix can 428 
be considered acceptable. For all other analytes, no matrix effects were 429 
measured, which indicates the absence of interferences by matrix 430 
compounds, stable-isotope-labeled internal standards, and co-eluting 431 
compounds, that may affect ion suppression and ion enhancement. The 432 
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matrix effect of plasma is relevant, although it does not influence 433 
quantification as all analytes and calibrators are prepared in the same 434 
plasma-matrix and are subject to influence to the same extent. 435 
Except for APAP-glutathione, the stability of all analytes was good, 436 
which means they were stable for at least 48 hours when stored at 6 °C. 437 
APAP-glutathione was only stable for 24 hours at 6 °C, and therefore the 438 
measurement or storage of the plasma sample in a freezer should be aimed 439 
for within 24 hours. This instability has also been reported by Cook et al. 440 
[30]. Hydrolysis of APAP-glutathione quickly transforms APAP-glutathione to 441 
APAP-cysteine, presumably by gamma-glutamyl transferase and 442 
dipeptidases. This may lead to an undervaluation of the actual concentration 443 
APAP-glutathione at the time of sample collection and may lead to an 444 
increased APAP-cysteine concentration. This instability of APAP-glutathione, 445 
where APAP-cysteine is formed from APAP-glutathione, may also be 446 
responsible for the increased recovery and process efficiency of APAP-447 
cysteine and the lower recovery and process efficiency of APAP-glutathione. 448 
For future research, the addition of peptidase inhibitors during sample 449 
collection could prevent or reduce this degradation. 450 
The assay was successfully validated for clinical practice and research 451 
purposes, quantifying acetaminophen and its metabolites in 162 plasma 452 
samples from children. APAP-glutathione could only be quantified in one 453 
sample, as a result of rapid conversion into APAP-cysteine. This confirms the 454 
relevance of the addition of a peptidase inhibitor during sample collection. 455 
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APAP-mercapturate could not yet be detected in five samples, which were 456 
all the first to be collected post dose, as APAP-mercapturate is the last 457 
metabolite to be formed. For one sample, which was drawn 4 minutes after 458 
the dose, all analytes were below LLOQ. Since acetaminophen was not yet 459 
detectable at that time, metabolites could not have been formed either. In 460 
conclusion, the assay is performing well for samples in clinical practice. 461 
Quantification of APAP-glutathione during therapeutic as well as toxic 462 
dosages of acetaminophen may be relevant, as it plays a crucial role in the 463 
formation of toxic metabolites, although quantification of in vivo APAP-464 
glutathione levels has only been reported in animals yet [29]. Normally, the 465 
reactive metabolite NAPQI is quickly detoxified by conjugation with 466 
glutathione and further converted to the cysteine conjugate before it is 467 
acetylated to form APAP-mercapturate. However, when the formation of 468 
the reactive metabolite exceeds the glutathione-conjugation capacity of the 469 
liver, covalent binding of NAPQI to cellular macromolecules may result, 470 
which initiates the events ultimately leading to cytotoxicity. 471 
Nevertheless, protein-derived APAP-cysteine can be measured with 472 
our assay if 130 µL of plasma sample is available. Generally, this allows the 473 
quantification in adults and older infants, but not in neonates. Protein-474 
derived APAP-cysteine is mostly present in hepatocytes and is directly 475 
related to toxicity and detectable in serum at therapeutic doses [6]. The 476 
interpretation for the treatment or toxicity still remains to be investigated. 477 
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More research is needed on the toxic effects and characteristics of 478 
acetaminophen metabolites in specific populations where different 479 
metabolism may be expected. These may include patients with anorexia, 480 
patients from different ethnic backgrounds, elderly patients, pregnant 481 
women and their fetuses [7], obese adults [5], preterm infants [32-34], 482 
patients with possible pharmacokinetic interactions on CYP1A2, and patients 483 
subjected to repeated administration of acetaminophen leading to induced 484 
CYP enzymes. Repeated administration of acetaminophen at a subtoxic dose 485 
may result in an induction of hepatic CYP enzymes CYP2E1, CYP3A, and 486 
CYP1A [35]. 487 
Generally, for toxicology purposes, acetaminophen concentrations 488 
have only been considered important to measure for patients who are 489 
suspected for intake of a toxic amount, not its metabolites. Extended 490 
knowledge is required about metabolite formation following intoxication to 491 
optimize treatment by infusion of the antidote, N-acetylcysteine. TDM of 492 
metabolites may be indicated in case of toxicity, or as part of standard 493 
clinical care in certain populations where metabolites may be used as a 494 
marker for suspected liver injury. 495 
 496 
CONCLUSION 497 
We have developed a method for the simultaneous quantification of 498 
APAP, APAP-glucuronide, APAP-sulfate, APAP-cysteine, APAP-glutathione, 499 
APAP-mercapturate, and protein-derived APAP-cysteine in human plasma, 500 
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which greatly facilitates further research into acetaminophen and 501 
metabolites, as well as for TDM purposes, even in the smallest plasma 502 
volumes obtained from preterm infants. 503 
 504 
 505 
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FIGURE LEGENDS 617 
Figure 1. Metabolic pathway of acetaminophen 618 
UDP:  Uridine 5’-diphospho-glucuronosyltransferase 619 
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Tables 1 
Table 1. Analyte-specific settings 2 
The bold printed product ion mass-to-charge values were chosen. 3 
Analyte Parent ion 
(m/z) 
Product ion 
(m/z) 
ESI mode Collision Energy 
(v) 
S-Lens 
APAP 152.169 110.16 
93.13 
65.13 
+ 15 
23 
29 
77 
APAP-D4 (IS) 156.191 114.19 
97.16 
69.17 
+ 15 
22 
30 
77 
APAP-D3-sulfate 235.017 155.06 
113.10 
68.10 
+ 26 
37 
31 
77 
APAP-sulfate 232.046 152.06 
110.10 
65.10 
+ 13 
22 
39 
77 
APAP-glucuronide  328.202 152.14 
110.07 
93.03 
+ 15 
35 
55 
80 
APAP-cysteine 271.155 182.08 
140.07 
96.07 
+ 12 
26 
37 
76 
APAP-mercapturate 313.176 208.10 
166.10 
140.050 
+ 16 
27 
31 
77 
APAP-glutathione 457.245 328.18 
181.89 
140.01 
+ 13 
22 
40 
110 
ESI: Electrospray ionization 4 
 5 
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 6 
Table 2. Validation results 7 
Analyte QC Accuracy
#
 
(%) 
Repeatability 
RSD (%) 
(within-run imprecision) 
Reproducibility 
RSD (%) 
(between-run imprecision) 
LLOQ 
(mg/L) 
ULOQ 
(mg/L) 
APAP QC L 
QC M 
QC H 
−2.6 
4.7 
1.9 
2.2 
2.4 
2.0 
5.0 
5.4 
6.1 
0.020 25.0 
APAP-cysteine QC L 
QC M 
QC H 
−4.9 
−0.4 
30.9 
5.9 
3.7 
4.1 
8.6 
6.9 
11.7 
0.020 10.0 
APAP-glucuronide QC L 
QC M 
QC H 
1.5 
−6.4 
4.6 
5.1 
3.8 
10.4 
5.7 
5.4 
12.4 
0.047 47.0 
APAP-glutathione QC L 
QC M 
QC H 
−4.0 
7.2 
−0.6 
6.6 
3.4 
3.6 
13.7 
6.4 
7.0 
0.022 43.0 
APAP-
mercapturate 
QC L 
QC M 
QC H 
2.2 
1.8 
−2.3 
3.6 
2.5 
3.4 
4.8 
4.7 
5.2 
0.010 15.0 
APAP-sulfate QC L 
QC M 
QC H 
−0.6 
0.8 
2.2 
3.1 
3.4 
3.1 
6.4 
4.4 
6.2 
0.043 43.0 
QC:  Quality control 8 
LLOQ:  Lower limit of quantification 9 
ULOQ:  Upper limit of quantification 10 
#
 The percentage for accuracy is the error of measurement. 11 
 12 
 13 
 14 
 15 
AC
CE
PT
ED
Copyright  2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
3 
 
 16 
Table 3. Matrix effect, recovery, and process efficiency 17 
Analyte Matrix effect 
mean (%) 
Recovery 
mean (%) 
Process Efficiency 
mean (%) 
APAP 90.3 108.2 97.7 
APAP-cysteine 104.5 122.2 127.6 
APAP-glucuronide 191.2 105.9 204.0 
APAP-glutathione 81.4 18.6 16.2 
APAP-mercapturate 72.0 140.3 96.4 
APAP-sulfate 95.8 104.5 100.2 
 18 
 19 
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